Peripheral arterial disease (PAD) is associated with metabolic derangements and accumulation of the common 4977 bp mitochondrial DNA (mtDNA) deletion mutation. The current study was undertaken to test the hypothesis that PAD is associated with multiple mtDNA deletions. Gastrocnemius biopsies were obtained from nine patients with unilateral PAD. DNA extracted from the biopsies was analyzed for mtDNA deletions using a primershift PCR strategy. Multiple primers and strict, prospective criteria were used to identify deletions. PAD was associated with multiple mtDNA deletions (average of 8.2 distinct deletions in muscle from the hemodynamically affected limb). mtDNA injury was present in both the worse-and less-affected limbs of the unilateral PAD patients, and the estimated degree of mtDNA injury was strongly correlated in the two limbs on an intra-subject basis. The 4977 bp deletion was frequently identified, but was not always the deletion of highest frequency in individual samples. The estimated relative frequency of the 4977 bp deletion was correlated with the overall mtDNA injury in the biopsies. In summary, PAD is associated with mtDNA injury as reflected by multiple deletion mutations. As the mutations are not limited to the ischemic limb in unilateral patients, they are unlikely to contribute to the pathophysiology of claudication.
Introduction
Accumulation of somatic mitochondrial DNA (mtDNA) mutations is associated with normal aging, [1] [2] [3] and is accelerated by a variety of chronic diseases. [4] [5] [6] [7] A large, 4977 base pair (bp) deletion in the mitochondrial genome has been particularly well studied. 8, 9 mtDNA injury has been postulated to result in a number of cellular sequelae, including enhanced mitochondrial free radical production and impaired mitochondrial oxidative ATP production. [10] [11] [12] However, the functional consequences of somatic mtDNA mutations have not been well defined in the pathophysiology of human disease. In particular, quantitation of individual mtDNA mutations in disease populations demonstrate large increases compared with control groups, but the absolute mutation frequencies are not of sufficient magnitude to affect mitochondrial function. 13 Skeletal muscle in patients with peripheral arterial disease (PAD) is characterized by a number of metabolic changes which are similar to those found in mitochondrial myopathies. [14] [15] [16] Additionally, the underlying atherosclerotic process in PAD and the repetitive ischemic-reperfusion insult to the lower extremity with walking exercise are associated with substantial oxidative stress. 17, 18 The metabolic changes in PAD appear to be of functional importance because biochemical parameters are strongly correlated with exercise capacity in patients with claudication. 19 Thus, while the initial lesion in PAD is atherosclerotic, secondary changes or injury to the affected skeletal muscle may contribute to disease pathophysiology.
Gastrocnemius muscle from patients with claudication contains an increased frequency of the common 4977 bp mtDNA deletion. 4 The frequency of the mutation is markedly increased in comparison to age-matched controls, but reaches levels of only approximately 0.8% of total mtDNA. 4 Additionally, the hemodynamically unaffected limb of patients with unilateral PAD also contains large amounts of the 4977 bp deletion. These observations suggest that the 4977 bp deletion is unlikely to be directly involved in the pathophysiology of claudication. The unilateral PAD model is of particular utility in elucidating the role of mtDNA injury because of the ability to access affected and unaffected muscle, and to integrate molecular changes with biochemical and physiologic status.
The 4977 bp deletion is only one of many identified potential mutations to the mitochondrial genome. The postulated mechanisms leading to the 4977 bp deletion would be predicted to yield other mutations under the same conditions, [20] [21] [22] and thus the 4977 bp deletion frequency may underestimate the total damage to the mtDNA pool. The region of the genome between nucleotides 8000 and 16 000 appears particularly prone to injury. 9,23,24 mtDNA expression in tissue will be dependent on the complete composition of the mtDNA pool. The current study was designed to test the hypothesis that PAD is associated with multiple mtDNA deletions in skeletal muscle of affected individuals.
Methods

Patient recruitment and muscle biopsy
Patients with unilateral PAD (n = 9) participated in the study after providing informed consent. Patients underwent a complete history and physical examination, assessment of ankle/brachial index (ABI; ratio of systolic blood pressure in lower to upper limb) and maximal exercise testing. 25 Unilateral PAD was defined as previously detailed, based on lateralizing hemodynamics and symptoms. 25 The limb with symptoms and an abnormal ABI is referred to as the worse-affected limb, and that without symptoms or ABI changes as the less-affected limb. Eight of the nine subjects were current smokers, and the ninth was a former smoker. None of the patients were diabetics. PAD patients underwent needle biopsies of each gastrocnemius muscle after a period of rest as described previously. 19 Samples were frozen immediately in liquid nitrogen and stored at −80°C until analysis.
DNA assays
Total cellular DNA was extracted from 10 to 20 mg of frozen muscle samples as previously described. 6 DNA was quantitated based on absorbence at 260 nm using an HP 9453 UV-Vis Spectrophotometer (Hewlett-Packard GmbH, Germany). This method reproducibly yielded 0.6-0.8 g DNA/mg wet weight gastrocnemius muscle.
Primer-shift polymerase chain reaction (PCR) was employed to identify mtDNA deletion mutations. 21, 26 Each DNA sample was analyzed under two PCR conditions (short-and long-PCR) to allow comprehensive analysis of the mitochondrial genome from base pair 8215 through 16 514 (numbering of mtDNA sequence as per Anderson et al 27 ) . Additionally, each sample was analyzed using six different pairs of primers (three upstream primers paired with each of two downstream primers) in each of the two PCR systems.
All PCR reactions were performed with Expand High Fidelity PCR reagents (Boehringer Mannheim, Indianapolis, IN, USA) as per the manufacturer's instructions. Amplifications of 50-60 ng template DNA were conducted in a total reaction volume of 50 l containing 200 nM of each primer and 0.2 mM of each NTP using a Ericomp EasyCycler (Ericomp, Inc, CA, USA).
Long-PCR utilized independent reactions containing one of three upstream primers (CTCTAGAGGCC-ACTGTAAAGCTAA, complimentary to 8285-8308; CCACAGTTTCATGCCCATCGTC, complimentary to 8194-8215; and TGAACCTACGAGTACACCGA, complimentary to 7901-7920) and one of two downstream primers (GTGGGCTATTTAGGCTTTATGACCCTG, complimentary to 16 540-16 514; and ATGATGT-CTGTGTGGAAAGTGGCTGTGC, complimentary to 282-255). PCR conditions were an initial 2 min denaturation at 94°C, followed by 30 cycles of denaturation for 15 s, primer annealing at 65°C for 30 s, and elongation at 68°C for 3 min. A final 7 min extension was performed at 72°C. Short-PCR utilized the same upstream primers as the long-PCR, but one of two distinct downstream primers (GGGGAAGCGAGGTTGACCTG, complimentary to 13 650-13 631; and CATGGGTAGAATCCGAGTATGTTG, complimentary to 13 928-13905). Amplification conditions were similar to the long-PCR, except annealing was done Vascular Medicine 2000; 5: 225-230 at 58°C for 40 s, and the first 10 cycles of elongation were done at 72°C for 75 s.
PCR reaction products (10 l) were size fractionated on 1.5% (long-PCR) or 2% (short-PCR) agarose gels and visualized with ethidium bromide. Each gel included DNA mass ladders in duplicate (Gibco BRL, Grand Island, NY, USA). The size of each product was determined and the size of the mtDNA deletion required to yield this product was calculated based on the primers used. For a specific deletion to be identified, the PCR product had to be present in four distinct PCR reactions utilizing two different upstream and two different downstream primers. Further, the product size from each reaction must have been within 5% of that predicted based on the calculated mean deletion size from the four reactions. The use of rigorous criteria for identifying mtDNA deletions is critical given the possibility of artifactual generation of PCR products. 13 The amount of each deletion present was semi-quantitatively estimated between 1+ and 4+ plus based on the signal intensity of the deletion product. This scoring system was examined in a subset of samples in which the 4977 bp deletion was specifically quantified. 4 For example, in 16 samples from the less-and worse-affected limbs of PAD patients, the zero to 4+ estimate of the 4977 bp frequency was correlated with the actual deletion frequency (r = 0.432; p Ͻ 0.1 data not shown). This comparison also suggested that the current methodology required a deletion of the frequency 0.1% to allow consistent detection. The individual performing the PCR reactions and analyses was blinded to the source of the samples.
The cumulative mtDNA injury in each muscle sample was described by two parameters. First, the number of distinct mutations meeting the above criteria was tallied. Secondly, a mtDNA injury index was calculated as the sum of the frequency estimates (each score being one through 4+) for each deletion identified in the sample. These parameters are not quantitative owing to the low sensitivity of the primer shift assay as discussed above, and the limited dynamic range of the 4+ scoring system. The parameters are tallied for qualitative depiction of the variability in injury across the population.
Data analysis
Data are expressed as the mean and standard error of the mean. Correlation analysis was done by linear regression.
Results
Gastrocnemius muscle biopsies from the worse-and lessaffected limbs of nine patients with unilateral PAD (Table  1) were analyzed for mtDNA deletions using the primershift PCR methodology. The use of multiple primers allowed identification of PCR products that unambiguously arose from mtDNA deletions in the muscle (Figure 1) .
A large number of distinct deletion mutations were identified in the muscle samples. Using the PCR product sizes, the deletion sizes were estimated. Deletions of similar size (within 100 bp) between samples were grouped for descriptive purposes, and the average estimated deletion size calculated. PAD-less and PAD-worse biopsies contained a spectrum of deletions, with few specific deletions present in more than one or two samples of each group (Figure 2) . However, deletions of approximately 4990 bp (presumably the 4977 bp common deletion) were seen in most of the samples. Deletions of approximately 2860, 3400, 3660, 3850, 3990, 4240, 5150, 5430, and 6050 bp were also seen in multiple samples from PAD patients. Interestingly, the 7400 bp deletion frequently seen in heart 28 was only rarely observed in gastrocnemius.
The degree of mtDNA injury was characterized by both the number of deletions identified per sample, and a cumulative estimate of the signal intensity for each deletion ( Table 2 ). The magnitude of mtDNA injury was similar in the PAD-worse and PAD-less affected limbs. The mtDNA injury index for the worse-and less-affected limbs was highly correlated on an intra-subject basis (r = 0.909, p Ͻ 0.001). However, the specific mutations identified in the worse-and less-effected limbs were often different in the same subject. While the 4977 bp deletion did not yield the strongest signal in all samples, its signal strength was correlated with the overall mtDNA injury index (e.g. r = 0.841, p Ͻ 0.01 in the PAD worse-affected limb samples). mtDNA injury in the worse-affected limb in the patients with unilateral PAD was not correlated to hemodynamics as defined by the ABI (r = −0.267, p = 0.487 ABI vs mtDNA injury index; n = 9). The mtDNA injury index was not correlated with the patients' functional status as reflected by claudication-limited peak VO 2 (r = −0.108, p = 0.781).
Discussion
Peripheral arterial disease is associated with metabolic features similar to those seen in mitochondrial myopathies, [14] [15] [16] and with the accumulation of the common 4977 bp mtDNA deletion mutation in skeletal muscle. 4 The 4977 bp deletion is most likely the result of oxidative damage to the mitochondrial genome, and as such, was hypothesized to be a marker of other injury to mtDNA. The current study demonstrates substantial injury to mtDNA in PAD and that mtDNA deletion mutations occur bilaterally in patients with unilateral PAD.
The presence of multiple mtDNA deletions in individual human tissue samples has been reported previously. 20, 22, [29] [30] [31] Care must be exercised in interpreting these reports because the extraordinary sensitivity of PCR may generate artifactual products owing to primer mis-pairings or incompletely generated products during early cycles of the amplification. 13 Indeed, many individual PCR reactions in the current study initially generated products subsequently not felt to reflect true deletions in the original template DNA (data not shown). The primer-shift methodology, 26 when combined with rigorous identification criteria such as used here, permits deletions to be identified with a high degree of confidence.
The mitochondrial genome is prone to oxidative injury, and this contributes to the generation of somatic mutations. 11, 12, 32 These mutations accumulate in an individual owing to mtDNA heteroplasmy, wherein multiple distinct sequences co-exist in the same tissue. 9 The co-existence of non-mutated mtDNA may allow the expression of functional mitochondria despite the presence of significant amounts of mutated sequence. Thus, in PAD, expression of cytochrome c oxidase activity is normal despite injury to the mtDNA in regions coding for cytochrome c oxidase subunits and tRNAs required for its translation. 4 In results similar to those reported here, Zhang and colleagues 33, 34 identified multiple mtDNA deletions in skeletal muscle and atrial tissue from elderly humans. Different specific mutations were identified in different individuals, similar to the findings of Figure 2 , but also in different regions of muscle from the same subject, 33, 34 This finding, similar to the identification of different mutations in the less-and worse-affected limbs of the same PAD patient despite similar degrees of overall mtDNA injury, emphasizes the non-specificity of the injury mechanism. The 4977 bp deletion was predictive of overall mtDNA injury in the PAD subjects in contrast to the lack of correlation in normal subjects reported by Zhang et al. 33 The current study provides further evidence that the mtDNA damage in PAD is not a result of local ischemia only. The less-affected limbs of the PAD patient show substantial amounts of 4977 bp deletions 4 and numerous other deletions ( Figure 2 and Table 2 ). The strong correlation between the degree of mtDNA in the worse-and less-affected limbs of the patients is also consistent with systemic oxidative stress as a potential cause of the multiple deletions. Indices of oxidative stress are elevated systemically in patients with PAD, 17, 18, 35, 36 and thus either the ischemic process or the underlying systemic atherosclerosis triggers a response not limited to the ischemic vascular bed.
Smoking, which is prevalent in the PAD population, has also been suggested to increase mtDNA injury, 37, 38 and may contribute to the mutations seen. Due to the prevalence of smoking in the current cohort, no assessment could be made as to the magnitude of the contribution of smoking to the mtDNA injury observed. Mitochondrial DNA mutations have also been detected in atherosclerotic lesions. 39 However, PAD is clearly associated with PAD mutation frequency independent of smoking and other host factors. 4 The primer shift assay is semi-quantitative at best, and specific quantitative approaches must be used to define absolute or relative mutation frequencies. 4, 13 For example, the primer-shift methodology was estimated to have a sensitivity sufficient to reliably detect deletions present at a frequency of at least 0.1%. The 4977 bp deletion was often present at frequencies less than 0.1% in PAD patients when assessed using quantitative methods. 4 Additionally, in contrast to the quantitative methods, 4, 40 the approach used in the current study does not correct for differential amplification efficiencies or staining intensities amongst distinct PCR products. Thus, the results of the primer shift assay should be viewed as descriptive of the spectrum of deletion mutations present in a sample.
While mtDNA mutations clearly cannot solely explain the metabolic derangements or the symptomatology in PAD, 4 they nevertheless may provide an insight into the underlying mechanisms. mtDNA mutations may be an index of oxidative stress, and thus reflect injury to other cellular constituents such as the proteins of the electron transport chain. 41 Animal models have clearly demonstrated the increased oxidative stress and mtDNA injury which result from mitochondrial dysfunction. 42 Additionally, subtle differences in mitochondrial function can perturb cellular regulation, 43 and mitochondrial myopathies respond to interventions directed against changes in intermediary metabolism similar to those in PAD. 14, 44, 45 Thus, in PAD, multiple deletion mutations are found in the skeletal muscle mtDNA pool. When combined with the previous quantitative analysis of the 4977 bp deletion, 4 it is clear that mtDNA deletions are present at low absolute frequencies and at similar levels in the less-and worseaffected limbs of patients with unilateral PAD. These mutations may reflect systemic oxidative stress, and do not correlate with functional aspects of the patients' disease. Care must be taken in linking the presence of somatic mtDNA mutations to causation in clinical syndromes (claudication) or to specific causative scenarios (i.e. local ischemia).
